Out-licensing and partnering · Technical review

The biotech licensing
due diligence checklist

A licensing partner is not buying a company. They are deciding whether one asset can leave your building and be developed in theirs, which is a far more specific question than any investor asks

Direct answer

Biotech licensing due diligence covers six evidence groups, each reviewed by a different specialist: the program data package, the intellectual property position including freedom to operate, the regulatory history with the agency, the chemistry manufacturing and controls record, quality and compliance, and the contracts that encumber the asset. Because the review is asset-level rather than company-level, the controlling test is transferability: whether a partner could reproduce the data, make the material and continue the regulatory path without you. Access is scoped to the program under discussion rather than opened wholesale.

Evidence groups06

Asset stages04

Reviewer lanes04

Editorial modelSource-led

01 · The checklist

Six groups a partner has to clear

Each group is reviewed by a different specialist inside the partner organization, and each can independently stop the deal. Organize the evidence the way it will be read, not the way it was created

Program data package

Every claim about the asset must be traceable to a protocol, a report and a dataset that a reviewer can open

Target rationale and mechanism evidence, including the experiments that failed to support alternatives
Pharmacology, pharmacokinetics and toxicology reports, with study conduct standards stated for each
Clinical protocols, amendments and the reason recorded for every amendment
Study reports, statistical analysis plans and the datasets behind the reported results
Safety database summary, individual case handling and any events that changed study conduct
Data provenance: which system produced each dataset, who locked it and when

Reviewed by · Clinical and translational scientists

Intellectual property and freedom to operate

Partners underwrite exclusivity for the life of the programme, so the rights analysis reaches further than a patent list

Patent families covering composition, method of use, formulation and process, with status by jurisdiction
Expected patent term including any adjustments and available extensions for the relevant jurisdictions
Complete assignment chain from each named inventor, covering prior employers and academic appointments
Freedom to operate analysis for the intended commercial form, with the search scope and date stated
In-licensed rights and the diligence, milestone, royalty and sublicensing obligations that travel with them
Government funding or institutional rights attached to any underlying research, with compliance status

Reviewed by · Patent counsel and transactional counsel

Regulatory history

The partner is inheriting a relationship with an agency, not only a dossier. That history has to be complete

Investigational application contents, submission history and current status
Meeting requests, briefing packages, agency minutes and written responses in full
Information requests, clinical holds if any, and the complete record of how each was resolved
Designations applied for or granted, with the supporting submissions
Any submissions to other health authorities and how they diverge from the position taken domestically
The current regulatory strategy, marked to separate agreed positions from company intentions

Reviewed by · Regulatory affairs reviewers

CMC and manufacturing

This is where transferability is really tested, and where a strong clinical story most often stalls

Process description and development history, including every change and the reason for it
Batch records and certificates of analysis for each batch used in reported studies
Analytical method descriptions with qualification or validation status and reference standards
Specifications and the justification for each acceptance criterion
Stability data supporting storage conditions, shelf life and shipping
Comparability assessment across process or site changes, and the technology transfer package

Reviewed by · Technical operations and CMC reviewers

Quality and compliance

Quality evidence tells a reviewer whether the records they just read can be relied on at all

Quality system documentation covering the activities performed for this programme
Deviation, investigation and corrective action records relevant to the material supplied
Audit history for internal sites and for contract manufacturers and laboratories
Any regulatory inspection history and the responses given
Supplier qualification status for critical materials and single-source dependencies
Data integrity practices covering electronic records and their audit trails

Reviewed by · Quality assurance

Contracts and encumbrances

The most common late failure is not weak data. It is an obligation nobody surfaced until counsel read the file

All agreements touching the asset: research, licence, option, supply, service and collaboration
Change of control, assignment and sublicensing provisions in each of them
Existing exclusivity, standstill or right of first negotiation commitments to other parties
Material transfer agreements and their restrictions on downstream use
Consulting and advisory agreements covering people who contributed to the programme
Confidentiality obligations that limit what can be disclosed in this diligence process

Reviewed by · Transactional counsel and alliance management

02 · Depth by asset stage

The later the asset, the less benefit of the doubt

A preclinical option deal and a Phase 3 licence ask the same six questions at very different depth. Preparing Phase 3 depth for an early asset wastes months; the reverse loses the deal

Asset stageManufacturing evidence expectedRegulatory evidence expectedWhat reviewers test hardest

Preclinical or optionProcess description, research batches, draft methodsPre-submission plan and any early agency interactionMechanism, reproducibility and the assignment chain

Phase 1Clinical batch records, qualified methods, early stabilityInvestigational application and safety reporting recordWhether the material in the study can be made again

Phase 2Comparability across changes, expanded stability, scale planMeeting minutes, information requests and responsesData provenance and the pre-specified analysis

Phase 3 and pre-submissionValidation-grade process, validated methods, supply chainSubmission readiness and the complete agency recordWhether the package survives an inspection and review

03 · Reviewer lanes

Four reviewers who each can stop the deal

Business development runs the process, but the verdict comes from specialists who review independently and rarely speak to each other during the technical diligence phase

Origination

Business development and search and evaluation

Reads for strategic fit, the competitive position of the mechanism, deal structure and the timeline to a decision point that matters inside their portfolio

Science

Clinical and regulatory reviewers

Read for whether the effect is real and the path is credible: pre-specification, data provenance, safety handling and what the agency has actually agreed to rather than been told

Supply

CMC and quality reviewers

Read for transferability: whether the process is described well enough to run elsewhere, whether methods are qualified, and whether the batch behind the data can be reproduced to specification

Rights

Patent counsel and alliance management

Read for what is actually being granted: claim scope, term, assignment completeness, obligations arriving from in-licensed components, and how the partnership will be governed afterwards

04 · Partner-specific access

Counterparties are often competitors

Partner-specific access is not administrative caution. The reviewers reading your programme may run a competing one, and the access design is part of the negotiation

Scope to the asset

Open the programme under discussion, not the pipeline. Other assets appear only where they are genuinely relevant, such as shared platform or manufacturing evidence

Name the reviewers

Access is granted to identified individuals under the confidentiality agreement rather than to an organization, so the record shows who saw what

Redact third-party terms

Financial terms in agreements with other parties are usually protected by confidentiality obligations, so they are redacted rather than withheld silently

Separate commercial material

Competitively sensitive commercial analysis stays outside the technical review, and the two lanes are opened on different timetables

Keep a reconstructable record

What each reviewer opened, when, and which version they saw remains reconstructable after the process closes, whether or not the deal happens

Close access deliberately

When discussions end, access ends on a defined date and the return or destruction obligations in the confidentiality agreement are actually executed

05 · Technical diligence questions

What the package is actually asked

Was this analysis pre-specified

Which analyses were defined in the statistical analysis plan before unblinding, and which were run afterwards and described as exploratory

Where did this dataset come from

Which system produced it, when was it locked, what changed after lock, and who can attest to the chain

Is the material comparable

What changed in the process between batches or sites, and what comparability evidence supports treating the resulting material as the same product

Are the methods qualified

For each analytical method behind a reported result, what is its qualification or validation status and where is the reference standard characterized

What did the agency actually say

Which positions appear in written minutes or responses, and which are the company's interpretation of a discussion

What travels with the rights

Which obligations, payments and restrictions arrive from in-licensed components or institutional agreements once the asset moves

06 · Update triggers

What forces the package to be refreshed

Any agency interaction

A meeting, written response or information request changes what the regulatory section can represent as agreed

Process or site change

A manufacturing change starts a comparability obligation and makes earlier batch evidence incomplete on its own

Patent office action

A grant, rejection, amendment or new filing changes claim scope, term and the exclusivity a partner is underwriting

New safety information

Any event affecting the benefit and risk picture moves the clinical package and the investigator materials at the same time

New third-party obligations

A new agreement, amendment or exclusivity commitment changes what can be granted and what must be disclosed in diligence

Editorial boundary This guide describes licensing evidence, not software suitability. See the data-room selection guide for documented provider use cases and disclosure of this site's commercial interest

07 · Questions and answers

Common questions about licensing diligence

What does a pharma partner review in biotech licensing due diligence?

Six evidence groups, each reviewed by a different specialist: the program data package, the intellectual property position including freedom to operate, the regulatory history with the agency, the chemistry manufacturing and controls record, quality and compliance, and the contracts that encumber the asset. Licensing diligence is asset-level rather than company-level, so the test is whether the specific program can be transferred and developed by someone else.

What belongs in a CMC due diligence checklist for licensing?

The manufacturing process description and its development history, the batch record and analysis for every batch used in reported studies, analytical method descriptions with their qualification or validation status, reference standards, specifications and the justification for them, stability data supporting storage and shelf life, comparability assessments across process changes, and the contract manufacturing agreements and technology transfer package. A partner is testing whether they could make the same material to the same specification without you.

How does licensing diligence differ from investor diligence?

An investor underwrites a company and its next value event. A licensing partner underwrites an asset they intend to develop themselves, so the review goes deeper on transferability: data provenance, manufacturing reproducibility, regulatory history with the agency, and whether the rights being licensed are clean and unencumbered. Technical diligence is run by working scientists and reviewers rather than by a deal team alone.

Should a licensing counterparty get access to the whole data room?

No. Partner-specific access is the norm because a counterparty is often a competitor in the same therapeutic area. Scope access to the asset under discussion, redact third-party financial terms that confidentiality obligations protect, keep competitively sensitive commercial material outside the technical review, and keep a record of what each named reviewer opened so the scope can be reconstructed later.

What derails licensing diligence most often?

Encumbrances and provenance gaps rather than disappointing data. Common examples are an in-licensed component carrying obligations that pass through to the partner, an assignment missing from the inventor chain, institutional or government rights attached to founding research, material used in a key study that cannot be reproduced under the current process, and analytical results that cannot be traced back to a qualified method.

08 · Primary sources

The official record a partner checks

Reviewers verify what they can against public systems before they ask you. These are the sources they use

IND

Investigational applications

What an investigational application must contain, how amendments work and what safety reporting is required during development

FDA guidance on investigational applications ↗

312

The underlying regulation

The rule text governing investigational studies, protocol amendments, clinical holds and sponsor obligations

21 CFR Part 312 ↗

MEET

Agency meetings

How formal meetings are requested, what a briefing package contains and how agreements reached are recorded in minutes

FDA guidance on formal meetings ↗

211

Manufacturing practice

Current good manufacturing practice requirements for finished pharmaceuticals, including records, testing and change control

21 CFR Part 211 ↗

Patent records

Published applications, granted claims, assignment records and prosecution history for the families a partner will rely on

USPTO Patent Public Search ↗

APP

Approved product records

Approval packages, labelling and review documents for approved products, used to benchmark a development path against precedent

Drugs@FDA ↗